OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 jun 2009 - 16:37
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron
Bericht
OctoPlus N.V. (“OctoPlus”) (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008.
Datum laatste update: 16 december 2025